Cadila Healthcare Q3 profit falls 6 percent to Rs 511 crore on rising expenses

Published On 2019-02-08 06:05 GMT   |   Update On 2019-02-08 06:05 GMT

Cadila Healthcare had posted a net profit of Rs 543.3 crore in the corresponding period of the previous fiscal, the drug firm said in a filing to BSE.


New Delhi: Cadila Healthcare on Thursday reported six per cent dip in consolidated net profit to Rs 510.7 crore for December quarter 2018, mainly on account of rising in expenses.


It had posted a net profit of Rs 543.3 crore in the corresponding period of the previous fiscal, the drug firm said in a filing to BSE.


Read Also: Cadila Healthcare gets EIR report from USFDA

Total revenue, however, rose to Rs 3,608.9 crore for the latest quarter as against Rs 3,285.6 crore in the same period of 2017-18.


Headquartered at Ahmedabad, the company is a pharmaceutical company in India with INR 54.7 Billion revenue (2015). It is a significant manufacturer of generic drugs.

Cadila was founded in 1952 by Ramanbhai Patel (1925–2001), formerly a lecturer in the L.M. College of Pharmacy, and his business partner Indravadan Modi. It evolved over the next four decades into an established pharmaceutical company


Also Read: Cadila Healthcare Q3 net profit rises 68 per cent to Rs 543 crore
Article Source : With input

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News